Expression and biological role of CIP2A in human astrocytoma.

@article{Yi2013ExpressionAB,
  title={Expression and biological role of CIP2A in human astrocytoma.},
  author={Fuxin Yi and Weimin Ni and Weixian Liu and Jin Bai and Wenbin Li},
  journal={Molecular medicine reports},
  year={2013},
  volume={7 5},
  pages={
          1376-80
        }
}
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently characterized oncoprotein involved in the progression of several human malignancies. The present study aimed to investigate the clinical significance and biological function of CIP2A in astrocytoma. CIP2A expression was analyzed in 135 archived astrocytoma specimens using immunohistochemistry. Of these specimens, 75 cases (55.6%) overexpressed CIP2A. The CIP2A overexpression was observed to be positively correlated with… 

Figures and Tables from this paper

Role of CIP2A in the antitumor effect of bortezomib in colon cancer.
TLDR
CIP2A was shown to be important in the bortezomib‑induced inhibitory effect on colon cancer, and was able to decrease the growth of tumors and was downregulated in the LoVo tumors treated with bortzomib.
Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme
TLDR
It is demonstrated that the overexpression of CIP2A promotes invasive behavior in GBM, and a natural compound, cucurbitacin B (CuB), shows an anti‐proliferative and anti‐invasion effect in G BM cell lines, rendering CuB as a promising candidate drug for further development and for designing new effective C IP2A inhibitors.
Overexpression of cancerous inhibitor ofPP2A (CIP2A) in acute myeloid leukemia
TLDR
CIP2A overexpression is a useful prognostic marker in AML and was shown to be a recurrent event in cytogenetic normal AML patients.
The role of CIP2A in cancer: A review and update.
CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus
TLDR
CIP2A may be a useful therapeutic target in CML-CP, particularly in patients with IM resistance, however, further studies are needed to validate the interaction between CIP2a and BCR-ABL using other tyrosine kinase inhibitors than IM.
Constitutive CHK1 Expression Drives a pSTAT3–CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth
TLDR
An oncogenic transcriptional circuit in GBM is identified that can be destabilized by targeting CIP2A, a known target of high-CHK1 activity, and the relationship between these two proteins in G BM is examined.
Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) Protein Is Involved in Centrosome Separation through the Regulation of NIMA (Never In Mitosis Gene A)-related Kinase 2 (NEK2) Protein Activity*
TLDR
It is demonstrated here that NIMA (never in mitosis gene A)-related kinase 2 (NEK2) is a binding partner for CIP2A, thereby enhancing NEK2 kinase activity to facilitate centrosome separation in a PP1- and PP2A-independent manner.
The Role of PME-1 in Cancer: Therapeutic Implication
TLDR
This study potentiates the candidacy of PME-1 as a therapy target in gliomas, but argues against generalization of these findings to other cancers, especially CRC, as colorectal cancer patients with high tumor PMe-1 expression display favorable prognosis.
Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Chronic Myeloid Leukaemia
TLDR
This thesis aimed to determine if CIP2A retained its potential prognostic indicator status in CML treated with dasatinib or nilotinib, and provides novel information about C IP2A in response to CML treatment, CIP1A protein interactions, Cip2A gene variations and epigenetic regulation.
CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma
TLDR
The presence of any two of the three indicated makers (CIP2A, galectin‐3, and HBME‐1) is strongly correlated with the diagnosis of PTC and the AUC for C IP2A was higher than those for other tumor markers.
...
...

References

SHOWING 1-10 OF 27 REFERENCES
Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients’ survival
TLDR
Higher-CIP2A expression positively correlates with the aggressive phenotype of RCCs, and predicts poor prognosis for patients, suggests cancerous inhibitor of protein phosphatase 2A may be a novel target for prevention and treatment of R CC metastasis and recurrence.
CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis
TLDR
CIP2A is an oncoprotein overexpressed in NSCLC, and its expression is associated with poor prognosis and malignant cell proliferation.
CIP2A Is Overexpressed in Gastric Cancer and Its Depletion Leads to Impaired Clonogenicity, Senescence, or Differentiation of Tumor Cells
TLDR
CIP2A in tumor cells is required for sustained proliferation by preventing cell growth arrest, senescence, or differentiation and its expression is significantly discriminatory between normal and cancerous gastric tissue.
CIP2A Is a Predictor of Poor Prognosis in Colon Cancer
TLDR
The knockdown of CIP2A reduced proliferation and anchorage-independent colony formation and increased 5-fluorouracil, oxaliplatin, and SN38 efficacy in colon cancer cell lines.
CIP2A is overexpressed in esophageal squamous cell carcinoma
A human oncoprotein-designed cancerous inhibitor of PP2A (CIP2A) has been recently identified, which can stabilize c-Myc protein by inhibiting its degradation mediated by protein phosphatase 2A
CIP2A Is Associated with Human Breast Cancer Aggressivity
TLDR
The data show that CIP2A is associated with clinical aggressivity in human breast cancer and promotes the malignant growth of breast cancer cells.
CIP2A expression is increased in prostate cancer
TLDR
Expression of the CIP2A protein is increased in prostate cancer specimens and its expression is associated with poorly differentiated and high-risk tumors.
Prognostic role of CIP2A expression in serous ovarian cancer
TLDR
The results show that CIP2A associates with reduced survival and parameters associated with high grade in ovarian cancer patients, and may thus be one of the factors that identify aggressive subtype (type II) of this disease.
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells
TLDR
In conclusion, inhibition of CIP2A determines the effects of bortezomib on apoptosis and PP2A-dependent Akt inactivation in HCC.
...
...